Herceptin, Trastuzumab News

Researchers say patients may want to consider adjuvant trastuzumab therapy Two retrospective studies led by researchers in the United States and Italy report that women with HER2-positive breast cancers 1 cm or less in diameter that have not spread to the lymph nodes have a risk of recurrence that is two to five times greater than that of women ...

However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy.

Women with a relatively uncommon type of breast cancer are significantly more likely to face its recurrence and spread, but researchers now say these women may benefit from treatment with the breast cancer drug Herceptin.

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab --typically used in combination with chemotherapy.

Ana M. Gonzalez-Angulo, M.D., is an associate professor in M. D. Anderson's Departments of Breast Medical Oncology and Systems Biology.

Canadian cardiologists have taken a step toward clearing the drug trastuzumab for use in the fight against breast cancer, even though it can cause serious heart complications in women.

E-mail: rosenn@mskcc.org Received 6 April 2009; Revised 22 July 2009; Accepted 9 September 2009; Published online 26 October 2009.

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr.

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze technology in a subcutaneous formulation with Roche's anticancer biologic, Herceptin .

In Her2-positive advanced breast cancer, the upfront use of trastuzumab is well established.

Breast Cancer Treatment Options by Stage - Continue from " Breast Cancer Treatment " A link to a list of current clinical trials is included for each treatment section.

A new report finds widespread variations and frequent errors in HER2 testing -- a procedure recommended for all patients with invasive breast cancer.

The correlation between tumor regression and molecular imaging of apoptosis, glucose metabolism, and cellular proliferation was evaluated longitudinally in responding and nonresponding tumor-bearing cohorts.

In the recent past, we discerned breast cancer prognosis and treatment by size, nodes and how it looked under the microscope.

New data identify a possible role for everolimus in reversing or delaying the onset of trastuzumab resistance in breast cancer patients.

Breast cancer therapy that's customized for each patient's personal genetic makeup is one step closer to reality, thanks to a new use for crime-lab technology pioneered at Roswell Park Cancer Institute .

Research and Markets has announced the addition of the "Expanding Applications of Personalized Medicine: Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach" report to their offering.

A protocol of carboplatin and weekly paclitaxel with or without trastuzumab produced "encouraging" pathological clearance in advance of definitive surgery in women with newly diagnosed stage IIA to IIIB breast cancer -- and particularly in those with more aggressive forms of the disease.

Allison M. Heinrichs can be reached via e-mail or at 412-380-5607. By Allison M. Heinrichs TRIBUNE-REVIEW Friday, September 25, 2009 A UPMC cancer doctor is playing an important role in an international clinical trial for a drug that has the potential to be the next big thing in breast cancer treatment.

Although information about the clinical use of human epidermal growth factor receptor 2 testing strategies in breast cancer patients is limited, evidence suggests that there are significant variations in testing practices and important knowledge gaps, according to a study published online Sept.